The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 6.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 0% above its long-term trend line with momentum reading bullish. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (21 analysts) rates it buy, with a mean price target of $65.
Amrize Ltd
AMRZ · the NYSE · USD · Market cap $23.4B · 19,000 employees
Amrize AG engages in the provision of various building solutions for infrastructure, commercial, and residential construction markets in North America.
PASS · Titan Ethical · score 70.0At the last full screen
2026-09-01
Screened 2026-09-01 · the tape above runs as of 11:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
This name holds its markdown label.
Amrize Ltd holds its Markdown at $42.81. Consolidating, no directional conviction, held for 24 days.
| Phase | Markdown · caution |
| Quantitative state | Consolidating, no directional conviction, held for 24 days |
| Price at the screen | $42.81 |
| Valuation | 19.20 trailing · 14.22 forward price to earnings |
| Values screen | PASS · score 70.0 |
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 26.16% | Below 33% | Interest-bearing debt is just 26.2% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 12.36% | Below 49% | Money owed to the company is 12.4% of assets, under the 49% limit. | Pass |
| Revenue purity | 0.00% | Below 5% | Only 0.0% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is WorthThe Fair Value Range
Fair value range in USD, drawn from the 2026-09-01 screen. The gold marker is the market price at the same screen. The price runs 3.7% above the base estimate.
Third-party analyst targets: 19 covering, consensus Buy. The average target sits +33% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-01 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsCement pours tied to the construction cycle
When a highway extension gets poured outside Dallas or a warehouse rises near Chicago, Amrize supplies the cement and aggregates that hold the project together. The business sits inside a sector that expands and contracts with interest rates, public spending and housing starts.
We pass. Shares trade 10% above our fair value, revenue growth sits at just 5% and the narrow moat plus 10% ROE give little margin when volumes turn down. A forward multiple of 15.6 times looks ordinary rather than cheap once the cycle is considered.
The classic trap in this industry is that earnings often peak while multiples still appear reasonable. Here the modest growth, single-country exposure and construction sensitivity add real downside if spending slows. Analysis, not advice.
| Forward P/E | 14.2xpriced for continued growth |
| Trailing P/E | 19.2xreasonably valued |
| EPS, trailing | 2.23 |
| EPS, forward | 3.01 |
| Revenue growth | +8.6%steady growth |
| Profit margin | 10.1%thin but positive margins |
| Return on equity | 9.7%a modest return on shareholder capital |
| FCF yield | 4.84% |
| Dividend yield | 22.00% |
| Debt to equity | 0.55moderate, manageable leverage |
| Current ratio | 1.10adequate liquidity, worth monitoring |
| Short interest, float | 0.01% |
| 52-week range | 42.72 - 65.94 |
| Moat | NARROW |
| Market cap | $23.4B |
| Employees | 19,000 |
The risks · The things to watch: its business and earnings are exposed to Switzerland and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeAMRZ trades on the NYSE (the company is based in Switzerland). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 6.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 0% above its long-term trend line with momentum reading bullish. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (21 analysts) rates it buy, with a mean price target of $65.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 0% above its long-term trend line with momentum reading bullish. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (21 analysts) rates it buy, with a mean price target of $65.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 0% above its long-term trend line with momentum reading bullish. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (21 analysts) rates it buy, with a mean price target of $65.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Amrize (AMRZ) Breaks Ground on Modernization Project at Saint-Constant Cement Plant Insider Monkey · 12 Jul 2026
- Amrize shares tumble as Truist downgrades on roofing pressures and cement pricing Investing.com · 7 Jul 2026
- Should You Buy Amrize (AMRZ)? Insider Monkey · 28 Jun 2026
- Here is Why Amrize (AMRZ) is One of the Best Young Stocks to Buy and Hold Insider Monkey · 6 May 2026
- Analysts Are Updating Their Amrize AG (VTX:AMRZ) Estimates After Its First-Quarter Results Simply Wall St. · 2 May 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 21 May2026 | Ro Khanna | Democrat | buy | 1K–15K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $51.93 | -1.7% | $0.11 | $985 | -1.5% |
| 2 months | $57.43 | -11.2% | $0.55 | $898 | -10.2% |
| 3 months | $55.75 | -8.5% | $0.55 | $925 | -7.5% |
| 6 months | $55.78 | -8.5% | $0.55 | $925 | -7.5% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever AMRZ does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.